508211-52-7

Basic information

• Product Name: Methyl 2-(benzyloxy)-5-nitrobenzenecarboxylate
• Synonyms: Methyl 2-(benzyloxy)-5-nitrobenzenecarboxylate
• CAS NO: 508211-52-7
• Molecular Formula: C₁₅H₁₃NO₅
• Molecular Weight: 287.26742
• Mol File: 508211-52-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 74-76°
• Appearance: /
• CAS DataBase Reference: Methyl 2-(benzyloxy)-5-nitrobenzenecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(benzyloxy)-5-nitrobenzenecarboxylate(508211-52-7)
• EPA Substance Registry System: Methyl 2-(benzyloxy)-5-nitrobenzenecarboxylate(508211-52-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 508211-52-7(Hazardous Substances Data)

Upstream product

• 17302-46-4 methyl 2-hydroxy-5-nitrobenzoate 
• 100-39-0 benzyl bromide 
• 67-56-1 methanol 
• 874523-84-9 2-benzyloxy-5-nitrobenzoic acid 

Relevant articles and documents

The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer

The estrogen-related receptor α (ERRα) is an orphan receptor and a novel target for solid tumor therapy, conceivably through effects on the regulation of tumor cell energy metabolism associated with energy stress within solid tumor micro environments. Here we describe the discovery of novel potent inverse agonists of ERRα. In?vitro, compound 11 potently inhibits ERRα’s transcriptional activity by preventing endogenous PGC-1α and ERRα binding and suppresses the proliferation of different human cancer cell lines and the migration of breast cancer cells (MDA-MB-231). In?vivo, compound 11 demonstrates a strong inhibitory effect on the growth of human breast cancer xenografts (MDA-MB-231) and the tumor growth is inhibited by 40.9% after treating with compound 11 (30?mg/kg). The binding mode shows that compound 11 interacts with the binding pocket of ERRα through hydrogen interactions with the residue Gly397 and hydrophobic interactions with the hydrophobic residues. All these results suggest that compound 11 represents a novel potent ERRα inverse agonist and is promising in the discovery of antitumor compounds for the treatment of triple negative breast cancer.

BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF

Novel benzene derivatives represented by the formula (I) : wherein R1, R4 and R6 each independently represents a hydrogen atom, a halogen atom or a hydrocarbon group, R2 represents a hydrocarbon group or a heterocyclic group, R3 represents a hydrocarbon group, NR7'R7 or OR8 (wherein R7' represents a hydrogen atom or a hydrocarbon group, R7 represents a non-aromatic group, or R7' and R7 may form a ring with the adjacent nitrogen atom, and R8 represents a hydrocarbon group or a heterocyclic group), R5 represents a hydrocarbon group or a heterocyclic group (except for a quinolyl group), R5' represents a hydrogen atom, or a hydrocarbon group, or R5 and R5' may form a ring with the adjacent nitrogen atom, and R5" represents a hydrogen atom or a hydrocarbon group, which have vanilloid receptor agonist activity and are useful as a drug such as an analgesic and an agent for preventing and/or treating urinary frequency and/or urinary incontinence.